With facilties in Palo Alto, CA and Lincoln MA., BrainStem Biometrics is focused on reducing risks and extending the lives of critical care patients who many times leave the ICU in worse shape than when they arrived, in part to sedative mis-management. Formed specifically to address the global problem of over-sedation in critical care the company has developed a unique sedation monitoring system that may allow clinicians to adjust medications to achieve target sedation levels. The firm's simple non-invasive low cost disposable sensor system is cleared by the FDA and enables ICU directors and health system executives to reduce costs and improve outcomes.The patent-protected technology is based on Ocular microtremor (OMT) or small nano-scale neurological impulse waves that emanate from deep inside the brainstem. The firm's non-invasive wearable sensor system is light weight, low cost and goes unnoticed by patients. The nature of illness in the ICU is very heterogeneous and patient needs can vary widely. A patient with head trauma requires different sedation management than a patient recovering from surgery. Targeted sedation goals for patients are difficult to achieve without an objective measurement of consciousness. It is widely accepted among critical care caregivers and administrators that a reliable tool for assessing sedation levels in the ICU is in great demand. This will allow for goal-directed sedative delivery with the ability to tailor sedation dosing optimally for each patient.
